Multiple Myeloma Faceoff: Fred Hutchinson Cancer Center vs City of Hope

EP. 1: Team Introductions: MM Experts From the Fred Hutchinson Cancer Center and City of Hope

ByAndrew J. Cowan, MD,Rahul Banerjee, MD, FACP,Vivian G. Oehler, MD,Paul B. Koller, MD,Lawrence W. Liu, MD,Murali Janakiram, MD, MS

September 12th 2023

An overview of the program agenda and introduction of expert panelists from the Fred Hutchinson Cancer Center and City of Hope teams.

EP. 2: Biochemical and Clinical Progression: The Two Faces of Relapsed MM

ByVivian G. Oehler, MD,Andrew J. Cowan, MD,Rahul Banerjee, MD, FACP,Paul B. Koller, MD,Lawrence W. Liu, MD,Murali Janakiram, MD, MS

September 12th 2023

Andrew Cowan, MD, discusses the complexities of relapsed multiple myeloma, distinguishing between biochemical and clinical progression, analyzing survival data, and raising questions about optimal treatment strategies.

EP. 3: Cross Q&A: Navigating Biochemical Relapse and MRD Resurgence in Multiple Myeloma

ByVivian G. Oehler, MD,Andrew J. Cowan, MD,Rahul Banerjee, MD, FACP,Paul B. Koller, MD,Lawrence W. Liu, MD,Murali Janakiram, MD, MS

September 19th 2023

An insightful discussion among specialists about the challenges of treating biochemical relapse and MRD resurgence in multiple myeloma patients, exploring nuanced considerations, patient collaboration, and the evolving landscape of treatment strategies.

EP. 4: Cross Q&A: Balancing Progression and Lines of Therapy at Myeloma Relapse

ByVivian G. Oehler, MD,Andrew J. Cowan, MD,Rahul Banerjee, MD, FACP,Paul B. Koller, MD,Lawrence W. Liu, MD,Murali Janakiram, MD, MS

September 19th 2023

Expert insights into tailoring treatment for biochemical relapse in multiple myeloma patients, considering disease progression and the impact of various therapy lines on treatment decisions.

EP. 5: REMIX Study: Ixa-Len-Dex for Relapsed/Refractory Myeloma

ByVivian G. Oehler, MD,Andrew J. Cowan, MD,Rahul Banerjee, MD, FACP,Paul B. Koller, MD,Lawrence W. Liu, MD,Murali Janakiram, MD, MS

September 26th 2023

Outcomes of the REMIX study investigating the effectiveness and tolerability of ixa-len-dex in real-world relapsed/refractory myeloma patients, exploring progression-free survival, overall response rate, and safety.

EP. 6: Cross Q&A: Exploring the Role of Ixazomib in Relapsed/Refractory Multiple Myeloma

ByVivian G. Oehler, MD,Andrew J. Cowan, MD,Rahul Banerjee, MD, FACP,Paul B. Koller, MD,Lawrence W. Liu, MD,Murali Janakiram, MD, MS

September 26th 2023

Key insights on real-world applications of the REMIX study, which evaluated real-world effectiveness and tolerability of the ixazomib-based regimen in relapsed/refractory multiple myeloma.

EP. 7: Ixa-Pom-Dex as Second-Line Therapy in Relapsed/Refractory MM: Alliance A061202

ByVivian G. Oehler, MD,Andrew J. Cowan, MD,Rahul Banerjee, MD, FACP,Paul B. Koller, MD,Lawrence W. Liu, MD,Murali Janakiram, MD, MS

October 3rd 2023

Rahul Banerjee, MD, FACP, discusses the Alliance A061202 trial, presenting the potential benefits and red flags of using ixazomib-pomalidomide-dexamethasone combination in relapsed myeloma treatment.

EP. 8: Debate on Efficacy and Patient Selection With Ixa-Pom-Dex in Relapsed/Refractory MM

ByVivian G. Oehler, MD,Andrew J. Cowan, MD,Rahul Banerjee, MD, FACP,Paul B. Koller, MD,Lawrence W. Liu, MD,Murali Janakiram, MD, MS

October 3rd 2023

Leading experts discuss the potential benefits and challenges of using ixazomib pomalidomide-dexamethasone as a treatment option for relapsed myeloma patients, considering factors like efficacy, overall survival, and patient demographics.

EP. 9: CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple Myeloma

ByVivian G. Oehler, MD,Andrew J. Cowan, MD,Rahul Banerjee, MD, FACP,Paul B. Koller, MD,Lawrence W. Liu, MD,Murali Janakiram, MD, MS

October 10th 2023

Panelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.

EP. 10: Fred Hutch and City of Hope “Face Off” on Ixazomib Vs Olverembatinib in CML and Multiple Myeloma

ByONCOLOGY Staff

October 19th 2023

Fred Hutch and City of Hope "Face Off" regarding presentations focusing on multiple myeloma and chronic myeloid leukemia.

Multiple Myeloma Faceoff: Fred Hutchinson Cancer Center vs City of Hope

EP. 1: Team Introductions: MM Experts From the Fred Hutchinson Cancer Center and City of Hope

EP. 2: Biochemical and Clinical Progression: The Two Faces of Relapsed MM

EP. 3: Cross Q&A: Navigating Biochemical Relapse and MRD Resurgence in Multiple Myeloma

EP. 4: Cross Q&A: Balancing Progression and Lines of Therapy at Myeloma Relapse

EP. 5: REMIX Study: Ixa-Len-Dex for Relapsed/Refractory Myeloma

EP. 6: Cross Q&A: Exploring the Role of Ixazomib in Relapsed/Refractory Multiple Myeloma

EP. 7: Ixa-Pom-Dex as Second-Line Therapy in Relapsed/Refractory MM: Alliance A061202

EP. 8: Debate on Efficacy and Patient Selection With Ixa-Pom-Dex in Relapsed/Refractory MM

EP. 9: CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple Myeloma

EP. 10: Fred Hutch and City of Hope “Face Off” on Ixazomib Vs Olverembatinib in CML and Multiple Myeloma

Trending on CancerNetwork

Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC

Response Rates Show Promise in Phase 1 trial Involving ASCT in Metastatic PDAC

What Path to Approval Has Dasatinib Taken in CML/ALL?

JSKN003 Receives FDA Fast Track Designation in Advanced PROC

SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC